Videos
Second-Line Therapy in Extranodal Marginal Zone Lymphoma
Perspective on Treating Advanced Marginal Zone Lymphoma
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Lung Cancer
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma
2
FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma
3
An Early Look at EHA 2026: 10 Key Studies Heading to Stockholm
4
FDA Grants RMAT Designation to Lasme-Cel for Relapsed/Refractory B-ALL
5